Paper · 28601352
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ and 12 others. Eur Urol, 2017. Cited by 185 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Papers, record 28601352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28601352
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Comparative Study, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics28
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Genomics | Major topic |
| Kidney Neoplasms | Major topic |
| Kidney Pelvis | Major topic |
| Multigene Family | Major topic |
| Mutation | Major topic |
| Ureter | Major topic |
| Ureteral Neoplasms | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Urothelium | Major topic |
| Aged | |
| Aged, 80 and over | |
| Cluster Analysis | |
| Computational Biology | |
| DNA Mutational Analysis | |
| Databases, Genetic | |
| Female | |
| Gene Expression Profiling | |
| Genetic Predisposition to Disease | |
| Humans | |
| Male | |
| Mutation Rate | |
| Phenotype | |
| Sequence Analysis, Protein | |
| Sequence Analysis, RNA | |
| Texas | |
| Treatment Outcome | |
| Exome Sequencing |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by123
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,985,052 | Advances in Novel Protein Acylation in Urothelial Carcinoma: Research Progress and Biomarker Potential. | Oncol Res | 2026 | https://conductscience.org/library/papers/42985052 | PubMed |
| 42,655,970 | Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. | Int J Urol | 2026 | https://conductscience.org/library/papers/42655970 | PubMed |
| 42,491,341 | Patient-derived organoid-immune co-cultures integrated with multi-omics reveal immunotherapy resistance mechanisms in urothelial carcinoma. | Imeta | 2026 | https://conductscience.org/library/papers/42491341 | PubMed |
| 42,137,465 | SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42137465 | PubMed |
| 41,954,652 | Stage-dependent prognostic impact of GATA3/FOXA1-defined luminal-like subtype in upper tract urothelial carcinoma. | Virchows Arch | 2026 | https://conductscience.org/library/papers/41954652 | PubMed |
| 41,893,002 | Urine-Based Approaches for Screening, Diagnosis, and Surveillance of Urothelial Carcinoma. | J Pers Med | 2026 | https://conductscience.org/library/papers/41893002 | PubMed |
| 41,740,229 | Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription. | EBioMedicine | 2026 | https://conductscience.org/library/papers/41740229 | PubMed |
| 41,701,175 | Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial. | Oncologist | 2026 | https://conductscience.org/library/papers/41701175 | PubMed |
| 41,680,729 | A 41-Year-Old male with multifocal "grape-like" ureteral carcinoma involving nearly the entire ureter: a case report and management discussion. | BMC Urol | 2026 | https://conductscience.org/library/papers/41680729 | PubMed |
| 41,568,223 | Neoadjuvant chemotherapy for high-risk upper tract urothelial cancer. | Bladder Cancer | 2026 | https://conductscience.org/library/papers/41568223 | PubMed |
1 to 10 of 123
See all 123 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CNTNAP5 | 129,684 | PubTator's text mining | https://conductscience.org/library/genes/129684 | NCBI Gene |
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| SH3KBP1 | 30,011 | PubTator's text mining | https://conductscience.org/library/genes/30011 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28601352
GET https://conductscience.org/api/papers/v1/28601352/cited_by?page=2